Downregulation of SIRT4 expression is associated with poor prognosis in esophageal squamous cell carcinoma

Yujiro Nakahara, Makoto Yamasaki, Genta Sawada, Yasuhiro Miyazaki, Tomoki Makino, Tsuyoshi Takahashi, Yukinori Kurokawa, Kiyokazu Nakajima, Shuji Takiguchi, Koshi Mimori, Masaki Mori, Yuichiro Doki

Research output: Contribution to journalArticle

10 Citations (Scopus)

Abstract

Objective: SIRT4, a mitochondria-localized sirtuin, represses glutamine metabolism by inhibiting glutamate dehydrogenase (GDH). The current study aimed to evaluate the clinical and biological significance of SIRT4 in esophageal squamous cell carcinoma (ESCC). Methods: The study comprised 172 patients with surgically resected ESCC in two independent cohorts. SIRT4 mRNA expression was analyzed in Cohort 1 (n = 79) and SIRT4 protein expression in Cohort 2 (n = 93). The association of SIRT4 expression with clinicopathological parameters and prognosis was assessed. Furthermore, the biological role of SIRT4 in ESCC cell lines was examined. Results: SIRT4 expression was not correlated with any clinicopathological parameters in both cohorts. In Cohort 1, low-SIRT4-expression cases had poorer overall survival than high-SIRT4-expression cases (p = 0.016). In Cohort 2, SIRT4-negative cases had poorer overall survival and disease-free survival than SIRT4-positive cases (p = 0.011 and 0.0026). Multivariate analysis revealed that SIRT4 expression was an independent prognostic factor for overall survival (HR = 2.06, p = 0.038). The rate of distant recurrence was significantly higher in SIRT4-negative cases than in SIRT4-positive cases (39.4 vs. 7.4%; p = 0.0023). In vitro, SIRT4 knockdown significantly increased GDH activity and promoted cell proliferation and migration. Conclusion: SIRT4 is a potential prognostic biomarker in ESCC.

Original languageEnglish
Pages (from-to)347-355
Number of pages9
JournalOncology (Switzerland)
Volume90
Issue number6
DOIs
Publication statusPublished - Jun 14 2016

Fingerprint

Down-Regulation
Glutamate Dehydrogenase
Survival
Glutamine
Disease-Free Survival
Cell Movement
Mitochondria
Multivariate Analysis
Biomarkers
Cell Proliferation
Recurrence
Cell Line
Messenger RNA
Esophageal Squamous Cell Carcinoma
Proteins

All Science Journal Classification (ASJC) codes

  • Oncology
  • Cancer Research

Cite this

Nakahara, Y., Yamasaki, M., Sawada, G., Miyazaki, Y., Makino, T., Takahashi, T., ... Doki, Y. (2016). Downregulation of SIRT4 expression is associated with poor prognosis in esophageal squamous cell carcinoma. Oncology (Switzerland), 90(6), 347-355. https://doi.org/10.1159/000445323

Downregulation of SIRT4 expression is associated with poor prognosis in esophageal squamous cell carcinoma. / Nakahara, Yujiro; Yamasaki, Makoto; Sawada, Genta; Miyazaki, Yasuhiro; Makino, Tomoki; Takahashi, Tsuyoshi; Kurokawa, Yukinori; Nakajima, Kiyokazu; Takiguchi, Shuji; Mimori, Koshi; Mori, Masaki; Doki, Yuichiro.

In: Oncology (Switzerland), Vol. 90, No. 6, 14.06.2016, p. 347-355.

Research output: Contribution to journalArticle

Nakahara, Y, Yamasaki, M, Sawada, G, Miyazaki, Y, Makino, T, Takahashi, T, Kurokawa, Y, Nakajima, K, Takiguchi, S, Mimori, K, Mori, M & Doki, Y 2016, 'Downregulation of SIRT4 expression is associated with poor prognosis in esophageal squamous cell carcinoma', Oncology (Switzerland), vol. 90, no. 6, pp. 347-355. https://doi.org/10.1159/000445323
Nakahara, Yujiro ; Yamasaki, Makoto ; Sawada, Genta ; Miyazaki, Yasuhiro ; Makino, Tomoki ; Takahashi, Tsuyoshi ; Kurokawa, Yukinori ; Nakajima, Kiyokazu ; Takiguchi, Shuji ; Mimori, Koshi ; Mori, Masaki ; Doki, Yuichiro. / Downregulation of SIRT4 expression is associated with poor prognosis in esophageal squamous cell carcinoma. In: Oncology (Switzerland). 2016 ; Vol. 90, No. 6. pp. 347-355.
@article{412831825c3e4aa8a11c6ed3d7be5e8c,
title = "Downregulation of SIRT4 expression is associated with poor prognosis in esophageal squamous cell carcinoma",
abstract = "Objective: SIRT4, a mitochondria-localized sirtuin, represses glutamine metabolism by inhibiting glutamate dehydrogenase (GDH). The current study aimed to evaluate the clinical and biological significance of SIRT4 in esophageal squamous cell carcinoma (ESCC). Methods: The study comprised 172 patients with surgically resected ESCC in two independent cohorts. SIRT4 mRNA expression was analyzed in Cohort 1 (n = 79) and SIRT4 protein expression in Cohort 2 (n = 93). The association of SIRT4 expression with clinicopathological parameters and prognosis was assessed. Furthermore, the biological role of SIRT4 in ESCC cell lines was examined. Results: SIRT4 expression was not correlated with any clinicopathological parameters in both cohorts. In Cohort 1, low-SIRT4-expression cases had poorer overall survival than high-SIRT4-expression cases (p = 0.016). In Cohort 2, SIRT4-negative cases had poorer overall survival and disease-free survival than SIRT4-positive cases (p = 0.011 and 0.0026). Multivariate analysis revealed that SIRT4 expression was an independent prognostic factor for overall survival (HR = 2.06, p = 0.038). The rate of distant recurrence was significantly higher in SIRT4-negative cases than in SIRT4-positive cases (39.4 vs. 7.4{\%}; p = 0.0023). In vitro, SIRT4 knockdown significantly increased GDH activity and promoted cell proliferation and migration. Conclusion: SIRT4 is a potential prognostic biomarker in ESCC.",
author = "Yujiro Nakahara and Makoto Yamasaki and Genta Sawada and Yasuhiro Miyazaki and Tomoki Makino and Tsuyoshi Takahashi and Yukinori Kurokawa and Kiyokazu Nakajima and Shuji Takiguchi and Koshi Mimori and Masaki Mori and Yuichiro Doki",
year = "2016",
month = "6",
day = "14",
doi = "10.1159/000445323",
language = "English",
volume = "90",
pages = "347--355",
journal = "Oncology",
issn = "0030-2414",
publisher = "S. Karger AG",
number = "6",

}

TY - JOUR

T1 - Downregulation of SIRT4 expression is associated with poor prognosis in esophageal squamous cell carcinoma

AU - Nakahara, Yujiro

AU - Yamasaki, Makoto

AU - Sawada, Genta

AU - Miyazaki, Yasuhiro

AU - Makino, Tomoki

AU - Takahashi, Tsuyoshi

AU - Kurokawa, Yukinori

AU - Nakajima, Kiyokazu

AU - Takiguchi, Shuji

AU - Mimori, Koshi

AU - Mori, Masaki

AU - Doki, Yuichiro

PY - 2016/6/14

Y1 - 2016/6/14

N2 - Objective: SIRT4, a mitochondria-localized sirtuin, represses glutamine metabolism by inhibiting glutamate dehydrogenase (GDH). The current study aimed to evaluate the clinical and biological significance of SIRT4 in esophageal squamous cell carcinoma (ESCC). Methods: The study comprised 172 patients with surgically resected ESCC in two independent cohorts. SIRT4 mRNA expression was analyzed in Cohort 1 (n = 79) and SIRT4 protein expression in Cohort 2 (n = 93). The association of SIRT4 expression with clinicopathological parameters and prognosis was assessed. Furthermore, the biological role of SIRT4 in ESCC cell lines was examined. Results: SIRT4 expression was not correlated with any clinicopathological parameters in both cohorts. In Cohort 1, low-SIRT4-expression cases had poorer overall survival than high-SIRT4-expression cases (p = 0.016). In Cohort 2, SIRT4-negative cases had poorer overall survival and disease-free survival than SIRT4-positive cases (p = 0.011 and 0.0026). Multivariate analysis revealed that SIRT4 expression was an independent prognostic factor for overall survival (HR = 2.06, p = 0.038). The rate of distant recurrence was significantly higher in SIRT4-negative cases than in SIRT4-positive cases (39.4 vs. 7.4%; p = 0.0023). In vitro, SIRT4 knockdown significantly increased GDH activity and promoted cell proliferation and migration. Conclusion: SIRT4 is a potential prognostic biomarker in ESCC.

AB - Objective: SIRT4, a mitochondria-localized sirtuin, represses glutamine metabolism by inhibiting glutamate dehydrogenase (GDH). The current study aimed to evaluate the clinical and biological significance of SIRT4 in esophageal squamous cell carcinoma (ESCC). Methods: The study comprised 172 patients with surgically resected ESCC in two independent cohorts. SIRT4 mRNA expression was analyzed in Cohort 1 (n = 79) and SIRT4 protein expression in Cohort 2 (n = 93). The association of SIRT4 expression with clinicopathological parameters and prognosis was assessed. Furthermore, the biological role of SIRT4 in ESCC cell lines was examined. Results: SIRT4 expression was not correlated with any clinicopathological parameters in both cohorts. In Cohort 1, low-SIRT4-expression cases had poorer overall survival than high-SIRT4-expression cases (p = 0.016). In Cohort 2, SIRT4-negative cases had poorer overall survival and disease-free survival than SIRT4-positive cases (p = 0.011 and 0.0026). Multivariate analysis revealed that SIRT4 expression was an independent prognostic factor for overall survival (HR = 2.06, p = 0.038). The rate of distant recurrence was significantly higher in SIRT4-negative cases than in SIRT4-positive cases (39.4 vs. 7.4%; p = 0.0023). In vitro, SIRT4 knockdown significantly increased GDH activity and promoted cell proliferation and migration. Conclusion: SIRT4 is a potential prognostic biomarker in ESCC.

UR - http://www.scopus.com/inward/record.url?scp=84975302275&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84975302275&partnerID=8YFLogxK

U2 - 10.1159/000445323

DO - 10.1159/000445323

M3 - Article

C2 - 27082627

AN - SCOPUS:84975302275

VL - 90

SP - 347

EP - 355

JO - Oncology

JF - Oncology

SN - 0030-2414

IS - 6

ER -